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background: High (HD) and low doses (LD) of the FXa inhibitor edoxaban (edox) were noninferior to warfarin in preventing stroke/systemic 
embolism (stroke/SEE) with less bleeding in the ENGAGE-AF trial of 21,105 pts with AF. Dose was reduced 50% for impaired drug clearance.
methods: We correlated edox dose, drug levels, and anti-FXa activity with efficacy and safety outcomes.
results: HD edox was superior to LD edox in preventing stroke/SEE; LD edox had less bleeding. Dose reduction resulted in a gradient of anti-FXa 
activity. Regardless of dose reduction, HD remained more efficacious than LD edox. Dose reduction resulted in even less bleeding with LD edox.
conclusion: A gradient of anti-FXa activity across a 4-fold range of edox doses suggests the therapeutic window is narrower for bleeding than 
thromboembolism
 
